Safety and efficacy of lenalidomide for patients with relapsed or refractory adult T cell leukemia/lymphoma post allogeneic hematopoietic stem cell transplantation, multi-institutional prospective observational trial

Safety and efficacy of lenalidomide for patients with relapsed or refractory adult T cell leukemia/lymphoma post allogeneic hematopoietic stem cell transplantation, multi-institutional prospective observational trial - Safety and efficacy of lenalidomide for relapsed or refractory ATL post allo-SCT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029635

Enrollment

Registered

2017-10-20

Start date

2017-10-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult T-cell leukemia-lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. relapsed or refractory adult T-cell leukemia-lymphoma patients who will be treated with lenalidomide 2. Positive for HTLV-1 antibody 3. Written informed consent 4. Compliance to Revmate

Exclusion criteria

Exclusion criteria: 1. History of lenalidomide administration after allogeneic hematopoietic stem cell transplantation 2. Plant to move within one year after registry 3. Inappropriate condition by physician's decision 4. Pregnancy or under breast-feeding or plat to pregnant during registry

Design outcomes

Primary

Measure	Time frame
One-year overall survival after hematopoietic stem cell transplantation	—

Countries

Japan

Contacts

Public ContactMakoto Yoshimitsu

Kagoshima University Hospital Department of Hematology and Immunology

myoshimi@m.kufm.kagoshima-u.ac.jp099-275-5934

Outcome results